Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1990-10-10
|
pubmed:abstractText |
The coadministration of growth hormone (GH) secretagogues can provide insight into the neuroregulation of GH secretion. The GH response to L-dopa (125, 250 and 500 mg orally for body weights less than 15 kg, between 15 and 30 kg and greater than 30 kg, respectively), arginine (Arg; 0.5 g/kg infused intravenously over 30 min) and galanin (GAL; 15 micrograms/kg infused intravenously over 60 min) when administered alone or combined with pyridostigmine (PD; 60 mg orally), a cholinergic agonist that likely acts via inhibition of endogenous somatostatin secretion, was studied in children with familial short stature. The GH-releasing effect of PD was also evaluated. In 8 children, PD and L-dopa when administered alone induced an equivalent GH rise (area under the response curve, mean +/- SEM: 241.4 +/- 31.1 vs. 202.9 +/- 38.6 micrograms/l/h) while their coadministration had an additive effect (435.4 +/- 41.4 micrograms/l/h; p less than 0.02 vs. PD and L-dopa alone). On the contrary, in other 8 children, PD and Arg induced similar GH increases either when administered alone (394.2 +/- 68.5 vs. 405.8 +/- 103.9 micrograms/l/h) or in combination (535.8 +/- 97.3 micrograms/l/h). GH increases almost superimposable were also observed when PD and GAL were administered alone (405.2 +/- 72.3 vs. 412.6 +/- 94.1 micrograms/l/h) or in combination (537.9 +/- 139.0 micrograms/l/h) in other 7 children. These data show that the enhancement of the cholinergic activity by PD increases the L-dopa-induced GH release but fails to modify both Arg- and GAL-induced GH release in short children.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/Galanin,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Neuropeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridostigmine Bromide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0028-3835
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
42-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1697660-Adolescent,
pubmed-meshheading:1697660-Arginine,
pubmed-meshheading:1697660-Child,
pubmed-meshheading:1697660-Drug Synergism,
pubmed-meshheading:1697660-Drug Therapy, Combination,
pubmed-meshheading:1697660-Female,
pubmed-meshheading:1697660-Galanin,
pubmed-meshheading:1697660-Growth Disorders,
pubmed-meshheading:1697660-Growth Hormone,
pubmed-meshheading:1697660-Humans,
pubmed-meshheading:1697660-Levodopa,
pubmed-meshheading:1697660-Male,
pubmed-meshheading:1697660-Neuropeptides,
pubmed-meshheading:1697660-Peptides,
pubmed-meshheading:1697660-Pyridostigmine Bromide
|
pubmed:year |
1990
|
pubmed:articleTitle |
Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.
|
pubmed:affiliation |
Department of Clinical Physiopathology, University of Turin, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|